FIGURE 3.

Difference in lung function change between 12 months pre- and post-nintedanib according to diagnostic group (n=123). Adjusted estimates of mean lung function a) forced vital capacity (FVC) (n=123), b) diffusing capacity of the lung for carbon monoxide (D_LCO) (n=113) and c) transfer coefficient of the lung for carbon monoxide (K_CO) (n=107) values at pre-initiation, initiation and post-initiation, and the difference in rate of lung function change pre- and post-initiation, according to diagnostic group. Estimates plotted with 95% confidence intervals. fHP: fibrotic hypersensitivity pneumonitis; CTD-ILD: connective tissue disease-associated interstitial lung disease.